20 articles
Super-resolution microscopy reveals how mitochondrial mRNAs are distributed, folded, and released during apoptosis inside living cells.
Researchers discover unique molecular patterns in lipedema patients and develop predictive models for this poorly understood condition affecting women.
FTO demethylase in AgRP neurons alters Kif1a splicing to boost neuropeptide release, promoting weight gain in mice.
Finnish study identifies distinct metabolic signatures for different genetic diabetes risk patterns, opening doors to personalized prevention.
A 6-month AI-driven personalized diet intervention cut BMI by 33% and reduced biological age by 8 years in morbidly obese patients.
Scientists developed a comprehensive genetic risk score that outperforms existing tests for predicting metabolic diseases across all ethnicities.
New research reveals genetic factors that determine individual responses to weight-loss medications like semaglutide.
Scientists identify how different immune cells use specific nutrient transporters, revealing new targets for autoimmune diseases.
New research reveals how SEC16B protein regulates glucose homeostasis by controlling insulin secretion in pancreatic beta cells.
New findings suggest genetic variants could explain why some patients lose more weight on semaglutide or tirzepatide — and why others suffer more side effects.
Large NHANES study reveals metabolic syndrome causes measurable acceleration in epigenetic aging clocks, offering new targets for intervention.
Transcriptomic analysis of Pseudomonas nitroreducens TX1 identifies 241 differentially expressed genes during surfactant degradation.
A novel conjugate merges GLP-1/GIP incretin signaling with pan-PPAR activation in one molecule, potentially revolutionizing metabolic therapy.
New research reveals how glucose metabolism directly controls fat tissue expansion through a novel epigenetic pathway involving JMJD1A.
New genetic analysis reveals how brain and fat tissue work together to regulate obesity and cardiovascular health.
New research reveals how the popular weight loss drug semaglutide works differently across three phases of treatment.
Novel GLP-1 analogue NNC5840 achieves greater weight reduction than semaglutide by optimizing receptor signaling bias rather than potency.
A comprehensive 2025 review framework matches GLP-1 agonists, tirzepatide, and other AOMs to specific obesity phenotypes, complications, and life stages.
Scientists identify MOXD1 as a driver of MASH and show blocking it with a small molecule reverses liver fat accumulation in mice.
New research reveals how cancer cells cluster together to switch their metabolism and successfully colonize distant organs.
